The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...
The former head of the Food and Drug Administration’s (FDA) drug division is joining Pfizer as its chief medical officer, the ...
Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...
Summit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida ...
Pfizer Inc. appointed the Food and Drug Administration’s former top drug reviewer to serve as its chief medical officer.
Patrizia Cavazzoni, formerly the top regulator of the drug division of the FDA, will join Pfizer as chief medical officer.
Discover insights from Summit Therapeutics' Q4 2024 earnings call, highlighting the Pfizer collaboration, ivonescimab trial expansions, and strong ...
Pfizer said on Monday former head of FDA's drug center, Patrizia Cavazzoni, will join the drugmaker as chief medical officer.
Pfizer (PFE) announced that Patrizia Cavazzoni will rejoin the company as Chief Medical Officer. Cavazzoni was most recently Director of the ...
Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results